A PHASE I/II DOSE ESCALATION STUDY OF INTRADERMAL GP160 TO EVALUATE SAFETY, DELAYED TYPE HYPERSENSITIVITY (SKIN TEST) RESPONSES AND IMMUNOGENICITY IN ASYMPTOMATIC HIV SEROPOSITIVE PATIENTS WITH MORE THAN 400 CD4+ CELLS: